Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety of Salbutamol Inhalers with Propellants HFA-152a and HFA-134a for Adults with Asthma

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the safety and tolerability of a medication called salbutamol sulfate, which is commonly used to treat asthma. Asthma is a condition that affects the airways in the lungs, making it difficult to breathe. The study will compare two different types of inhalers that deliver salbutamol: one using a new propellant called HFA-152a and the other using the standard propellant HFA-134a. Both inhalers are designed to help relieve asthma symptoms by opening up the airways.

The purpose of the study is to evaluate the long-term safety of these inhalers over a period of three months. Participants in the study will be randomly assigned to use one of the two inhalers. Some participants may receive a placebo, which looks like the real inhaler but does not contain the active medication. The study will be conducted in a way that neither the participants nor the researchers know which inhaler each participant is using, to ensure unbiased results.

Throughout the study, participants will use their assigned inhaler as needed for asthma relief. They will attend regular check-ups to monitor their health and any side effects they may experience. The study aims to provide valuable information on the safety of the new propellant in the inhalers, which could lead to improved treatment options for people with asthma.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Initial Assessment

    Upon joining the study, eligibility is confirmed based on age (18 years or older) and a history of asthma for at least 6 months.

    An initial assessment includes a lung function test to measure the forced expiratory volume (FEV1) to ensure it is at least 60% of the predicted value.

    Asthma control is evaluated using the Asthma Control Questionnaire (ACQ) with a score below 1.5 indicating eligibility.

  2. Step 2

    Run-in Period

    Participants enter a run-in period to stabilize their asthma treatment. This involves maintaining a consistent dose of inhaled corticosteroids (ICS) or a combination of ICS and long-acting beta-agonists (LABA).

    Participants must refrain from using short-acting beta-agonists (SABA) for at least 6 hours and LABA for 24 hours before spirometry tests.

  3. Step 3

    Randomization and Treatment

    Participants are randomly assigned to receive salbutamol via a metered dose inhaler (MDI) with either the test propellant HFA-152a or the reference propellant HFA-134a.

    The treatment period lasts for 3 months, during which participants use the inhaler as a rescue medication for asthma symptoms.

  4. Step 4

    Monitoring and Follow-up

    Throughout the 3-month treatment period, participants are monitored for any adverse effects.

    Regular follow-up visits are scheduled to assess the safety and tolerability of the treatment.

  5. Step 5

    Completion of Study

    At the end of the 3-month period, a final assessment is conducted to evaluate the overall safety and effectiveness of the treatment.

    Participants complete the study and receive information on the results and any further steps if necessary.

Who can join the trial?

6 criteria

  • The participant must be at least 18 years old at the time of signing the informed consent, or a legal guardian must provide written consent for them.
  • The participant must have had asthma for at least 6 months. This means they should have a documented history of asthma and be receiving a stable dose of asthma treatment for at least 12 weeks before the study starts. The treatment should remain stable during the study.
  • The participant's asthma should be controlled, with no severe worsening in the last 6 months. Severe worsening means needing systemic corticosteroids (medications taken by mouth, injection, or suspension) for at least 3 days, or needing to go to the hospital or emergency department because of asthma.
  • The participant must have a baseline lung function test result (called FEV1) that is at least 60% of what is predicted for their age and size. FEV1 is a measure of how much air a person can forcefully exhale in one second.
  • The participant must show evidence of airway reversibility. This means their FEV1 should increase by at least 12% and 200 mL within 20 to 60 minutes after using an inhaled short-acting beta-agonist (a type of asthma medication). If they don't meet this requirement on the first try, they can try again within 7 days.
  • The participant should be able to avoid using short-acting beta-agonists for at least 6 hours and long-acting beta-agonists for at least 24 hours before lung function tests.

Who cannot join the trial?

8 criteria

  • Individuals under 18 years of age cannot participate.
  • People who do not have a diagnosis of asthma are excluded. Asthma is a condition where the airways in the lungs become narrow, making it hard to breathe.
  • Participants who are not able to use an inhaler properly are excluded. An inhaler is a device that helps deliver medicine directly into the lungs.
  • Individuals with other serious health conditions that might interfere with the study are not allowed to join.
  • Pregnant or breastfeeding women cannot participate in the study.
  • People who have participated in another clinical trial recently may be excluded.
  • Individuals with a known allergy to the study medication or its ingredients cannot take part.
  • Participants who are unable to follow the study procedures or attend scheduled visits are excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Salbutamol: This medication is used as a rescue treatment for asthma. It helps to quickly relieve symptoms such as wheezing, coughing, and shortness of breath by relaxing the muscles in the airways and improving airflow to the lungs. In this trial, salbutamol is administered using a metered dose inhaler (MDI) with two different types of propellants, HFA-152a and HFA-134a, to evaluate their long-term safety.

What is already known about the treatment

Salbutamol – Salbutamol is administered through a metered dose inhaler (MDI), which is a device that delivers the medication directly to the lungs. It is currently being studied in clinical trials to assess its long-term safety when used with different propellants in inhalers. The main therapeutic use of salbutamol is to relieve symptoms of asthma, such as wheezing and shortness of breath. It works by relaxing the muscles in the airways, making it easier to breathe. Salbutamol is classified as a bronchodilator, specifically a beta-2 adrenergic agonist, which means it targets specific receptors in the lungs to open up the airways.

Investigated diseases

Asthma – Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty in breathing. It often presents with symptoms such as wheezing, coughing, shortness of breath, and chest tightness. These symptoms can vary in intensity and may be triggered by factors like allergens, exercise, cold air, or stress. Asthma is marked by episodes of exacerbation, known as asthma attacks, where symptoms become more severe. The condition can affect individuals of all ages, but it often begins in childhood. Management typically involves avoiding triggers and using medications to control symptoms and prevent attacks.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-509001-76-00Protocol code220735Estimated enrolment460 patientsSponsorGlaxosmithkline Research & Development Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).